PAclitaxel-eluting Balloon in Primary PCI in Amsterdam; Pilot Study (PAPPA-pilot)

• Major acute coronary event [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]

  Defined as

  1. any death in which cardiac cause can not be excluded (death due to proximate cardiac cause, unwitnessed death, death of unknown cause, all procedure-related deaths)
  2. recurrent MI in the target vessel area (if no infarct localization is identified it is regarded target vessel related)
  3. target lesion revascularization (PCI within 5mm of the balloon(stent) area borders or CABG of the target vessel)
  
  

• Cross-over to bail-out stenting [ Time Frame: 1, 6 and 12 months ] [ Designated as safety issue: No ]
  
• Death from any cause [ Time Frame: 1, 6 and 12 months ] [ Designated as safety issue: Yes ]
  
• Major acute coronary event [ Time Frame: 6 and 12 months ] [ Designated as safety issue: Yes ]

  Defined as

  1. any death in which cardiac cause can not be excluded (death due to proximate cardiac cause, unwitnessed death, death of unknown cause, all procedure-related deaths)
  2. recurrent MI in the target vessel area (if no infarct localization is identified it is regarded target vessel related)
  3. target lesion revascularization (PCI within 5mm of the balloon(stent) area borders or CABG of the target vessel)
  
  
• In-hospital major acute coronary event [ Time Frame: index hospitalisation ] [ Designated as safety issue: Yes ]

  Defined as, in-hospital index event:

  1. any death in which cardiac cause can not be excluded (death due to proximate cardiac cause, unwitnessed death, death of unknown cause, all procedure-related deaths)
  2. recurrent MI in the target vessel area (if no infarct localization is identified it is regarded target vessel related)
  3. target lesion revascularization (PCI within 5mm of the balloon(stent) area borders or CABG of the target vessel)
  
  
• Recurrent MI non-target vessel related [ Time Frame: 1, 6 and 12 months ] [ Designated as safety issue: Yes ]
  
• Target vessel revascularisation [ Time Frame: 1, 6 and 12 months ] [ Designated as safety issue: No ]
  Target vessel revascularisation, but not target lesion revasularisation (is primary outcome measure)
  
  
• Stroke [ Time Frame: 1, 6 and 12 months ] [ Designated as safety issue: Yes ]
  objectified and documented by a physician
  
  
• Stent thrombosis [ Time Frame: index hospitalisation, 1, 6 and 12 months ] [ Designated as safety issue: Yes ]
  according tot the ARC criteria
  
  
• NON-CABG major bleeding [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
  as in HORIZON trial
  
  
• Hemorrhagic events [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
  according to TIMI bleeding classification
  
  

Multiple randomized clinical trials and pooled analyses have shown improved clinical outcomes of primary PCI when compared with fibrinolytic therapy. Primary PCI for STEMI results in greater patency of the infarct-related artery (IRA) and lower rates of death, re-infarction, and stroke when compared with fibrinolysis. The use of coronary stents has reduced the need for repeat revascularization in patients treated with primary PCI. However, in the setting of STEMI this reduction in target lesion revascularization (TLR) did not reduce re-infarction rates or both short term and long-term mortality rates. This was confirmed by a large meta-analysis by De Luca et al, using 13 randomized trials and involving 6922 patients. In studies evaluating DES versus BMS in STEMI mortality rates are similar in patients treated with BMS or DES. Although TLR rates are reduced with the use of DES, there have been concerns about long-term delay of arterial healing produced by both the Cypher DES and Taxus DES and the associated risk of late stent thrombosis. Anti-proliferative drugs in DES used to prevent neointimal hyperplasia also prevent the formation of an epithelial surface at the inner side of stents causing possible stent malapposition and potentionally late stent thrombosis. A new approach in treatment of STEMI is now available by the development of a drug eluting balloon. These DEB can be used with or without additional stent placement. Potential advantages compared to DES are a more homogeneous drug distribution, short lasting exposure and a higher local drug dose. Moreover, when no additional stent is needed, it might reduce the need for long term aggressive anti-platelet therapy in order to prevent acute, late or very late stent thrombosis. In short, DEB provides the potential advantage of delivering a anti-proliferative drug, without the disadvantage of leaving a coronary stent, in STEMI patients treated with primary PCI. The use of DEB is already tested for treatment of de novo coronary lesions and in-stent restenosis and has been shown to be a feasible and safe.In this clinical evaluation the use of the CE-marked Paclitaxel-eluting balloon with provisional stenting for STEMI will be evaluated on top of current highest standard therapy.